Ironwood Pharmaceuticals (IRWD) Retained Earnings (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Retained Earnings data on file, last reported at -$1.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 555523.47% year-over-year to -$1.6 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.6 billion (down 555523.47% YoY), and the FY2025 full-year result was -$1.1 million, up 99.94% from the prior year.
• Retained Earnings slipped to -$1.6 billion in Q1 2026, from -$1.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $294000.0 in Q1 2025 to a low of -$1.7 billion in Q2 2023.
• A 5-year average of -$614.4 million and a median of -$650.7 million in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings surged 131.89% in 2025 and tumbled 555523.47% in 2026, its largest moves.
• Tracing IRWD's Retained Earnings over 5 years: stood at -$696.4 million in 2022, then soared by 99.56% to -$3.0 million in 2023, then slumped by 55912.37% to -$1.7 billion in 2024, then jumped by 99.94% to -$1.1 million in 2025, then sank by 153951.42% to -$1.6 billion in 2026.
• Business Quant data shows IRWD's Retained Earnings at -$1.6 billion in Q1 2026, -$1.1 million in Q4 2025, and -$1.7 billion in Q3 2025.